Cadila Healthcare receives New Approvals, strengthen Zydus’ US product basket

Cadila Healthcare Ltd has announced that the Company has received three product approvals from the USFDA in quick succession. The group has received approvals to market Azathioprine Tablets 50 mg and tentative approvals for Divalproex Sodium Extended Release Tablets 250 and 500 mg and Venlafaxine Hydrochloride Tablets 25, 37.5, 50, 75 and 100 mg.

The branded sales in the US market of Azathioprine Tablets, which falls in the immuno- suppresant segment, was estimated at USD 113 million in 2006 as per NDC. The branded sales of Divalproex Sodium Extended Release, an anti-convulsant, was estimated at USD 700 million in 2006 and that of Venlafaxine Hydrochloride Tablets, an anti-depressant, was estimated at USD 141 million in 2006 as per NDC.

The Company will market all the three drugs through its US subsidiary Zydus Pharmaceuticals (USA) Inc. The group now has 22 approvals since the commencement of filing process in FY 2003-04. So far, the group has filed 46 ANDAs and 46 DMFs.

Source : Equity Bulls

Keywords